Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of candida by use of clsi methods and interpretive criteria

Journal of Clinical Microbiology

Volumn 52, Issue 1, 2014, Pages 108-114

  Pfaller, Michael A ^a,b   Messer, Shawn A ^a   Diekema, Daniel J ^b   Jones, Ronald N ^a   Castanheira, Mariana ^a  

^a JMI LABORATORIES   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; MICAFUNGIN;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BROTH DILUTION; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; CLINICAL AND LABORATORY STANDARD INSTITUTE; CONTROLLED STUDY; EPIDEMIOLOGICAL CUTOFF VALUES; ERROR; FUNGAL STRAIN; FUNGUS ISOLATION; GENE MUTATION; INTERPRETIVE CRITERIA; KLUYVEROMYCES MARXIANUS; MAJOR ERROR; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; MINOR ERROR; NONHUMAN; PICHIA GUILLIERMONDII; PREDICTION; PRIORITY JOURNAL; VERY MAJOR ERROR; WILD TYPE;

ANTIFUNGAL AGENTS; BIOLOGICAL MARKERS; CANDIDA; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FUNGAL PROTEINS; HUMANS; LIPOPEPTIDES; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 84891511343     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02481-13     Document Type: Article

References (46)

1. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Flörl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ, ESCMID Fungal Infection Study Group. 2012. ESCMID guideline for the diagnosis and management of Candida diseases 2012: Non-neutropenic adult patients. Clin. Microbiol. Infect. 18(Suppl 7):19-37. http://dx.doi.org/10.1111/ 1469-0691.12039.
2. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD, Infectious Diseases Society of America. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535. http://dx.doi.org/10.1086/596757.
3. Ullmann AJ, Akova M, Herbrecht R, Viscoli C, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Calandra T, Castagnola E, Cornely OA, Donnelly JP, Garbino J, Groll AH, Hope WW, Jensen HE, Kullberg BJ, Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Cuenca-Estrella M, ESCMID Fungal Infection Study Group. 2012. ESCMID guideline for the diagnosis and management of Candida diseases 2012: Adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT). Clin. Microbiol. Infect. 18(Suppl 7):53-67. http://dx.doi.org/10.1111/ 1469-0691.12041.
4. Arendrup MC, Garcia-Effron G, Lass-Flörl C, Lopez AG, Rodriguez-Tudela JL, Cuenca-Estrella M, Perlin DS. 2010. Echinocandin susceptibility testing of Candida species: Comparison of EUCAST EDef 7.1, CLSI M27-A3, Etest, disk diffusion, and agar dilution methods with RPMI and isosensitest media. Antimicrob. Agents Chemother. 54:426-439. http://dx.doi.org/10.1128/AAC.01256-09.
5. Arendrup MC, Pfaller MA, Danish Fungaemia Study Group. 2012. Caspofungin Etest susceptibility testing of Candida species: Risk of misclassification of susceptible isolates of C. glabrata and C. krusei when adopting the revised CLSI caspofungin breakpoints. Antimicrob. Agents Chemother. 56:3965-3968. http://dx.doi.org/10.1128/AAC.00355-12.
6. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S, Jones RN, Turnidge J, Diekema DJ. 2010. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J. Clin. Microbiol. 48:52-56. http://dx.doi.org/10.1128/JCM.01590-09.
7. Arendrup MC, Park S, Brown S, Pfaller M, Perlin DS. 2011. Evaluation of CLSI M44-A2 disk diffusion and associated breakpoint testing of caspofungin and micafungin using a well-characterized panel of wild-type and fks hot spot mutant Candida isolates. Antimicrob. Agents Chemother. 55:1891-1895. http://dx.doi.org/10.1128/AAC.01373-10.
8. Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. 2013. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: Application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J. Clin. Microbiol. 51:2571-2581. http://dx.doi.org/10.1128/JCM.00308-13.
9. Pfaller MA, Diekema DJ, Andes D, Arendrup MC, Brown SD, Lockhart SR, Motyl M, Perlin DS, CLSI Subcommittee for Antifungal Testing. 2011. Clinical breakpoints for the echinocandins and Candida revisited: Integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14:164-176. http://dx.doi.org/10. 1016/j.drup.2011.01.004.
10. Arendrup MC, Cuenca-Estrella M, Lass-Flörl C, Hope W, EUCASTAFST. 2012. EUCAST technical note on the EUCAST definitive document EDef 7.2: Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for yeasts EDef 7.2 (EUCAST-AFST). Clin. Microbiol. Infect. 18:E246-E247. http://dx.doi.org/10.1111/j.1469-0691.2012.03880.x.
11. Arendrup MC, Garcia-Effron G, Buzina W, Mortensen KL, Reiter N, Lundin C, Jensen HE, Lass-Flörl C, Perlin DS, Bruun B. 2009. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: Laboratory characteristics and implication for susceptibility testing. Antimicrob. Agents Chemother. 53:1185-1193. http://dx.doi.org/10.1128/ AAC.01292-08.
12. Arendrup MC, Rodriguez-Tudela JL, Park S, Garcia-Effron G, Delmas G, Cuenca-Estrella M, Gomez-Lopez A, Perlin DS. 2011. Echinocandin susceptibility testing of Candida spp. using EUCAST EDef 7.1 and CLSI M27-A3 standard procedures: Analysis of the influence of bovine serum albumin supplementation, storage time, and drug lots. Antimicrob. Agents Chemother. 55:1580-1587. http://dx.doi.org/10.1128/AAC.01364-10.
13. Espinel-Ingroff A, Arendrup MC, Pfaller MA, Bonfietti LX, Bustamante EB, Canton E, Chryssanthou E, Cuenca-Estrella M, Dannaoui E, Fothergill A, Fuller J, Gaustad P, Gonzalez GM, Guarro J, Lass-Flörl C, Lockhart SR, Meis JF, Moore CB, Ostrosky-Zeichner L, Pelaez T, Pukinskas SRBS, St-Germain G, Szeszs MW, Turnidge J. 9 September 2013. Interlaboratory variability of caspofungin MICs for Candida spp. using CLSI and EUCAST methods: Should the clinical laboratory be testing this agent? Antimicrob. Agents Chemother. http://dx.doi.org/10.1128/AAC.01519-13.
14. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, Rex JH, Alexander BD, Andes D, Brown SD, Chaturvedi V, Ghannoum MA, Knapp CC, Sheehan DJ, Walsh TJ. 2008. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: Analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46:2620-2629. http://dx.doi.org/10.1128/JCM. 00566-08.
15. Garcia-Effron G, Lee S, Park S, Cleary JD, Perlin DS. 2009. Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-d-glucan synthase: Implication for the existing susceptibility breakpoint. Antimicrob. Agents Chemother. 53:3690-3699. http://dx.doi.org/10.1128/AAC.00443-09.
16. Garcia-Effron G, Chua DJ, Tomada JR, DiPersio J, Perlin DS, Ghannoum M, Bonilla H. 2010. Novel FKS mutations associated with echinocandin resistance in Candida species. Antimicrob. Agents Chemother. 54: 2225-2227. http://dx.doi.org/10.1128/AAC.00998-09.
17. Perlin DS. 2011. Echinocandin-resistant Candida: Molecular methods and phenotypes. Curr. Fungal Infect. Rep. 5:113-119. http://dx.doi.org/10.1007/ s12281-011-0054-x.
18. Lepak A, Castanheira M, Diekema D, Pfaller M, Andes D. 2012. Optimizing echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations. Antimicrob. Agents Chemother. 56: 5875-5882. http://dx.doi.org/10. 1128/AAC.01102-12.
19. Spreghini E, Orlando F, Sanguinetti M, Posteraro B, Giannini D, Manso E, Barchiesi F. 2012. Comparative effects of micafungin, caspofungin, and anidulafungin against a difficult-to-treat fungal opportunistic pathogen, Candida glabrata. Antimicrob. Agents Chemother. 56:1215-1222. http://dx.doi.org/10.1128/AAC.05872-11.
20. Howard SJ, Livermore J, Sharp A, Goodwin J, Gregson L, Alastruey-Izquierdo A, Perlin DS, Warn PA, Hope WW. 2011. Pharmacodynamics of echinocandins against Candida glabrata: Requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts. Antimicrob. Agents Chemother. 55:4880-4887. http://dx.doi.org/10.1128/AAC.00621-11.
21. Arendrup MC, Perlin DS, Jensen RH, Howard SJ, Goodwin J, Hope W. 2012. Differential in vivo activity of anidulafungin, caspofungin and micafungin against C. glabrata isolates with and without FKS resistance mutations. Antimicrob. Agents Chemother. 56:2435-2442. http://dx.doi.org/10.1128/AAC.06369- 11.
22. Alexander BD, Johnson MD, Pfeiffer CD, Jiménez-Ortigosa C, Catania J, Booker R, Castanheira M, Messer SA, Perlin DS, Pfaller MA. 2013. Increasing echinocandin resistance in Candida glabrata: Clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin. Infect. Dis. 56:1724-1732. http://dx.doi.org/10.1093/cid/cit136.
23. Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, Grenouillet F, Cassaing S, Baixench MT, Bretagne S, Dromer F, Lortholary O, French Mycoses Study Group. 2012. Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg. Infect. Dis. 18:86-90. http://dx.doi.org/10.3201/eid1801.110556.
24. Durán-Valle MT, Gago S, Gómez-López A, Cuenca-Estrella M, Díez-Canseco LJ, Gómez-Garcés JL, Zaragoza O. 2013. Recurrent episodes of candidemia due to Candida glabrata with a mutation in the hot spot 1 of the FKS2 gene developed after prolonged therapy with caspofungin. Antimicrob. Agents Chemother. 56:3417-3419. http://dx.doi.org/10.1128/AAC.06100-11.
25. Lortholary O, Desnos-Ollivier M, Sitbon K, Fontanet A, Bretagne S, Dromer F, French Mycosis Study Group. 2011. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: A prospective multicenter study involving 2,441 patients. Antimicrob. Agents Chemother. 55:532-538. http://dx.doi.org/10.1128/AAC.01128-10.
26. Pfeiffer CD, Garcia-Effron G, Zaas AK, Perfect JR, Perlin DS, Alexander BD. 2010. Breakthrough invasive candidiasis in patients on micafungin. J. Clin. Microbiol. 48:2373-2380. http://dx.doi.org/10.1128/JCM.02390-09.
27. Shields RK, Nguyen MH, Press EG, Updike CA, Clancy CJ. 2013. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrob. Agents Chemother. 57:3528-3535. http://dx.doi.org/10.1128/AAC.00136-13.
28. Desnos-Ollivier M, Moquet O, Chouaki T, Guérin AM, Dromer F. 2011. Development of echinocandin resistance in Clavispora lusitaniae during caspofungin treatment. J. Clin. Microbiol. 49:2304-2306. http://dx.doi.org/10. 1128/JCM.00325-11.
29. Jensen RH, Johansen HK, Arendrup MC. 2013. Stepwise development of a homozygous S80P substitution in Fks1p, conferring echinocandin resistance in Candida tropicalis. Antimicrob. Agents Chemother. 57:614-617. http://dx.doi.org/10.1128/AAC.01193-12.
30. Healey KR, Katiyar SK, Castanheira M, Pfaller MA, Edlind TD. 2011. Candida glabrata mutants demonstrating paradoxical caspofungin reduced susceptibility but micafungin increased susceptibility. Antimicrob. Agents Chemother. 55:3947-3949. http://dx.doi.org/10.1128/AAC.00044-11.
31. Healey KR, Katiyar SK, Raj S, Edlind TD. 2012. CRS-MIS in Candida glabrata: Sphingolipids modulate echinocandin-Fks interaction. Mol. Microbiol. 86:303-313. http://dx.doi.org/10.1111/j.1365-2958.2012.08194.x.
32. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ. 2004. Cross-resistance between fluconazole and ravuconazole and the use of fluconazole as a surrogate marker to predict susceptibility and resistance to ravuconazole among 12,796 clinical isolates of Candida spp. J. Clin. Microbiol. 42:3137-3141. http://dx.doi.org/10.1128/JCM.42.7.3137-3141.2004.
33. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Diekema DJ. 2007. Use of fluconazole as a surrogate marker to prvedict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. tested by Clinical and Laboratory Standards Instituterecommended broth microdilution methods. J. Clin. Microbiol. 45:70-75. http://dx.doi.org/10.1128/ JCM.01551-06.
34. Pfaller MA, Messer SA, Boyken L, Tendolkar S, Hollis RJ, Diekema DJ. 2008. Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: Resultsfrom a global antifungal surveillance program. J. Clin. Microbiol. 46:551-559. http://dx.doi.org/10.1128/JCM.01952-07.
35. Howell SA, Hazen KC. 2011. Candida, Cryptococcus, and other yeasts of medical importance, p 1793-1821. In Versalovic J, Carroll KC, Funke G, Jorgensen JH, Landry ML, Warnock DW (ed), Manual of clinical microbiology, 10th ed. ASM Press, Washington, DC.
36. Castanheira M, Woosley LN, Diekema DJ, Messer SA, Jones RN, Pfaller MA. 2010. Low prevalence of fks1 hotspot 1 mutations in a worldwide collection of Candida spp. Antimicrob. Agents Chemother. 54:2655-2659. http://dx.doi.org/10. 1128/AAC.01711-09.
37. Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. 2012. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J. Clin. Microbiol. 50:1199-1203. http://dx.doi.org/10.1128/JCM.06112-11.
38. Clinical and Laboratory Standards Institute. 2012. Reference method for broth dilution antifungal susceptibility testing of yeasts; 4th informational supplement. CLSI M27-S4. Clinical and Laboratory Standards Institute, Wayne, PA.
39. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard-3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
40. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing; 23rd informational supplement. CLSI M100-S23. Clinical and Laboratory Standards Institute, Wayne, PA.
41. Pfaller MA, Diekema DJ. 2012. Progress in antifungal susceptibility testing of Candida spp. by use of Clinical and Laboratory Standards Institute broth microdilution methods, 2010 to 2012. J. Clin. Microbiol. 50:2846-2856. http://dx.doi.org/10.1128/JCM.00937-12.
42. Clinical and Laboratory Standards Institute. 2008. Development of in vitro susceptibility testing criteria and quality control parameters; approved standard-3rd ed. CLSI document M23-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
43. Ferraro MJ, Jorgensen JH. 1995. Instrument-based antibacterial susceptibility testing, p 1379-1384. In Murray PR, Baron EJ, Pfaller MA, Tenover FC, Yolken RH (ed), Manual of clinical microbiology, 6th ed. ASM Press, Washington, DC.
44. Jones RN, Pfaller MA, SENTRY Antimicrobial Surveillance Program Participants Group (USA). 2001. Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin? Report from the SENTRY Antimicrobial Surveillance Program (1997-99). Diagn. Microbiol. Infect. Dis. 39:237-243. http://dx.doi.org/10.1016/S0732-8893(01)00229-2.
45. Slater JL, Howard SJ, Sharp A, Goodwin J, Gregson LM, Alastruey-Izquierdo A, Arendrup MC, Warn PA, Perlin DS, Hope WW. 2011. Disseminated candidiasis caused by Candida albicans with amino acid substitutions in Fks1 at position Ser645 cannot be successfully treated with micafungin. Antimicrob. Agents Chemother. 55:3075-3083. http://dx.doi.org/10.1128/AAC.01686-10.
46. Turnidge J, Paterson DL. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin. Microbiol. Rev. 20:391-408. http://dx.doi.org/10.1128/CMR.00047-06.